Sanara Medtech Stock Fundamentals
| SMTI Stock | USD 37.70 0.38 1.02% |
Sanara Medtech fundamentals help investors to digest information that contributes to Sanara Medtech's financial success or failures. It also enables traders to predict the movement of Sanara Stock. The fundamental analysis module provides a way to measure Sanara Medtech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanara Medtech stock.
As of now, Sanara Medtech's Gross Profit is increasing as compared to previous years. The Sanara Medtech's current Other Operating Expenses is estimated to increase to about 72.7 M, while Operating Income is projected to decrease to (4.4 M). Sanara | Select Account or Indicator |
Sanara Medtech Company Return On Equity Analysis
Sanara Medtech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sanara Medtech Return On Equity | -0.2 |
Most of Sanara Medtech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanara Medtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Sanara Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Sanara Medtech has a Return On Equity of -0.2028. This is 99.15% lower than that of the Health Care Equipment & Supplies sector and 96.61% lower than that of the Health Care industry. The return on equity for all United States stocks is 34.58% lower than that of the firm.
Sanara Medtech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sanara Medtech's current stock value. Our valuation model uses many indicators to compare Sanara Medtech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sanara Medtech competition to find correlations between indicators driving Sanara Medtech's intrinsic value. More Info.Sanara Medtech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Sanara Medtech's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sanara Medtech's earnings, one of the primary drivers of an investment's value.Sanara Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanara Medtech's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanara Medtech could also be used in its relative valuation, which is a method of valuing Sanara Medtech by comparing valuation metrics of similar companies.Sanara Medtech is currently under evaluation in return on equity category among its peers.
Sanara Medtech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sanara Medtech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sanara Medtech's managers, analysts, and investors.Environmental | Governance | Social |
Sanara Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0508 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 345.19 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Shares Owned By Insiders | 66.56 % | ||||
| Shares Owned By Institutions | 9.42 % | ||||
| Number Of Shares Shorted | 202.97 K | ||||
| Price To Book | 8.28 X | ||||
| Price To Sales | 4.22 X | ||||
| Revenue | 64.99 M | ||||
| Gross Profit | 39.48 M | ||||
| EBITDA | (289.1 K) | ||||
| Net Income | (4.3 M) | ||||
| Cash And Equivalents | 12.68 M | ||||
| Cash Per Share | 1.53 X | ||||
| Total Debt | 11.79 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 4.55 X | ||||
| Cash Flow From Operations | (3.25 M) | ||||
| Short Ratio | 7.49 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 44.0 | ||||
| Number Of Employees | 107 | ||||
| Beta | 1.56 | ||||
| Market Capitalization | 329.54 M | ||||
| Total Asset | 73.87 M | ||||
| Retained Earnings | (28.04 M) | ||||
| Working Capital | 5.24 M | ||||
| Net Asset | 73.87 M |
About Sanara Medtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanara Medtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanara Medtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanara Medtech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 12 K | 11.4 K | |
| Total Revenue | 65 M | 68.2 M | |
| Cost Of Revenue | 7.9 M | 8.2 M | |
| Stock Based Compensation To Revenue | 0.05 | 0.05 | |
| Sales General And Administrative To Revenue | 1.15 | 1.75 | |
| Research And Ddevelopement To Revenue | 0.06 | 0.03 | |
| Revenue Per Share | 7.85 | 8.24 | |
| Ebit Per Revenue | (0.06) | (0.07) |
Currently Active Assets on Macroaxis
When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:Check out Sanara Medtech Piotroski F Score and Sanara Medtech Altman Z Score analysis. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 9.241 | Quarterly Revenue Growth 0.352 | Return On Assets (0.05) | Return On Equity (0.20) |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.